Deucravacitinib in dermatology: current indication and existing off-label data

Tyrosine kinase 2 (TYK2) inhibition has recently emerged as a novel therapeutic strategy in dermatology, targeting key cytokine pathways involved in immune-mediated inflammatory diseases. Deucravacitinib, an oral, selective TYK2 inhibitor that binds the regulatory pseudokinase domain, modulates sign...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Michela D’Agostino, Luca Potestio, Nello Tommasino, Matteo Megna
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BioExcel Publishing Ltd 2026-06-01
Serie:	Drugs in Context
Soggetti:	dermatology deucravacitinib immunemediated inflammatory diseases psoriasis real-world evidence tyk2 inhibition
Accesso online:	https://www.drugsincontext.com/deucravacitinib-in-dermatology-current-indication-and-existing-off-label-data/
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!